The transcription factor NF-κB is essential for liver homeostasis, as it is involved in controlling the balance between survival and death signals ([@bib14]). Upon ligand binding, distinct receptors stimulate the IKK complex (IKK1/IKKα, IKK2/IKKβ, and IKKγ/NEMO), which initiates NF-κB activation. The regulatory subunit IKKγ/NEMO is crucial during this process, as NEMO deletion results in complete NF-κB inhibition and embryonic lethality.

Hepatocyte-specific deletion of NEMO and its consequent NF-κB inhibition has detrimental effects on liver homeostasis, as it promotes spontaneous steatohepatitis, fibrosis progression, and development of hepatocellular carcinoma (HCC; [@bib13]). Additionally, NEMO deletion in hepatocytes promotes severe TNF-mediated liver damage ([@bib2]). However, the impact of other TNF-related cytokines on acute liver injury and their contribution to the development of the strong parenchymal damage observed in hepatocyte-specific NEMO-deleted (NEMO^Δhepa^) mice remains unknown.

FasL and TNF-related apoptosis-inducing ligand (TRAIL) belong to the TNF family of cytokines, as they signal through death receptors which contain cytoplasmic death domains ([@bib21]). Activation of the FasL/Fas system leads to massive apoptotic cell death and fulminant hepatitis ([@bib19]). More recently, liver steatosis has been shown to hypersensitize hepatocytes to Fas-mediated apoptosis, contributing to the progression of steatohepatitis and end-stage liver disease ([@bib30]).

TRAIL, via its receptor DR5, selectively induces apoptosis of transformed and virally infected hepatocytes, and NF-κB--dependent signaling counteracts its detrimental effects ([@bib15]). The cellular responses to TRAIL have been related to the inflammatory status of the liver, and DR5 up-regulation can be mediated by free fatty acids and bile acids, indicating a link between fat metabolism and TRAIL signaling ([@bib7]; [@bib16]). This is supported by findings showing high levels of liver DR5 expression in nonalcoholic steatohepatitis patients ([@bib16]). Additionally, fatty liver disease activates the innate immune system by triggering NKT cells, promoting an unbalanced Th1/Th2 response in the liver ([@bib3]). This contributes to create a proinflammatory environment where high IFN-γ expression is found. Furthermore, IFN-γ produced by activated NKT cells strongly induces NK cells to express TRAIL ([@bib22]).

Together, these data suggest that FasL and TRAIL could be involved in mediating the severe liver phenotype observed in NEMO^Δhepa^ mice. In the present study, we aimed to characterize the implication of these cytokines and to uncover the pathophysiological mechanisms contributing to liver inflammation and further disease progression in NEMO^Δhepa^ animals.

We demonstrate that NEMO^Δhepa^ mice are resistant to Fas-mediated apoptosis, whereas they are hypersensitive to TRAIL-mediated cell death. Moreover, we highlight an essential role for NK cells, the main producers of TRAIL, in the spontaneous phenotype observed in NEMO^Δhepa^ mice, as interfering with this cascade significantly improved liver homeostasis and attenuated the impact of T cell--mediated hepatitis in NEMO^Δhepa^ mice.

RESULTS AND DISCUSSION
======================

To better characterize the role of NEMO in hepatocytes, we generated NEMO loxP mice and crossed them with alfp-Cre transgenic animals to create NEMO^f/f^ (WT) and NEMO^Δhepa^ (KO) mice ([Fig. S1, A and B](http://www.jem.org/cgi/content/full/jem.20082152/DC1)). Hepatocyte-specific NEMO deletion led to a complete lack of NF-κB activation after TNF stimulation, confirming our previous results (Fig. S1 C; [@bib13]). Additionally, in consonance with our previous data ([@bib13]), NEMO^Δhepa^ animals exhibited spontaneously elevated TNF and TNFR1 levels, although no significant differences were found in TNFR2 expression (Fig. S1 D). Immunohistochemistry (IHC) confirmed higher TNF expression in the nonparenchymal cell compartment in NEMO^Δhepa^ mice (Fig. S1 D). Moreover, 12-wk-old NEMO^Δhepa^ mice displayed high ALT levels (Fig. S1 E), accompanied by signs of nonalcoholic steatohepatitis, activation of progenitor cells, profuse inflammation, and features of chronic liver damage such as hepatocyte dysplasia and anisokaryosis (Fig. S1 F, top). The combination of these events contributed to HCC development in 1-yr-old NEMO^Δhepa^ mice, as indicated by liver tumors and higher liver weight/body weight ratio (Fig. S1, F \[bottom\] and G).

Hepatocyte-specific NEMO deletion promotes hypersensitivity to exogenously administered TNF; however, the animals survived this challenge ([@bib2]). As NEMO deletion may also contribute to amplifying liver damage triggered by other TNF-related cytokines, we sought to investigate their implication in mediating the liver phenotype of NEMO^Δhepa^ mice.

Fas activation promotes acute hepatic failure ([@bib19]). Hence, stimulation with an anti-Fas mAb (Jo2, 0.5 µg/g) resulted in the death of all NEMO^f/f^ mice within 10 h ([Fig. 1 A](#fig1){ref-type="fig"}). Unexpectedly, NEMO^Δhepa^ animals were less sensitive to Jo2, as 90% of the mice survived ([Fig. 1 A](#fig1){ref-type="fig"}). Macroscopic view confirmed that NEMO^Δhepa^ livers remained unaffected while NEMO^f/f^ showed significant blood accumulation and a higher liver weight/body weight ratio ([Fig. 1 B](#fig1){ref-type="fig"}). Accordingly, NEMO^f/f^ mice showed clear signs of fulminant hepatitis, as high ALT levels, infiltrating PMN and RBC, necrosis, and apoptotic bodies were observed ([Fig. 1, C and D](#fig1){ref-type="fig"}). In contrast, we failed to detect any significant effects of Jo2 in NEMO^Δhepa^ mice, as only the preexisting elevated ALT levels and parenchymal damage, caused by the spontaneous phenotype of these mice, was observed ([Fig. 1, C and D](#fig1){ref-type="fig"}). TUNEL assay, caspase 8, and caspase 3 activity confirmed resistance to Fas-induced apoptosis in NEMO^Δhepa^ mice ([Fig. 1, E and F](#fig1){ref-type="fig"}).

![**Hepatocyte-specific NEMO-deleted mice (NEMO^Δhepa^) are protected against Fas-mediated apoptosis.** (A) Survival curve after i.p. injection of 0.5 µg/g Jo2, evidencing the resistance of NEMO^Δhepa^ mice to Fas-mediated death. (B--D) Macroscopic view of livers 3 h after Jo2 (B), liver weight/body weight ratio (B), serum transaminases (C), and H&E staining (D) showed fulminant hepatitis in NEMO^f/f^ mice after Jo2, whereas NEMO^Δhepa^ remained unaffected. (E and F) TUNEL (E) and caspase 8 and 3 (F) activity analysis confirmed Jo2 apoptosis. Activity is represented in times versus untreated NEMO^f/f^. (G and H) Fas mRNA and IHC analysis in whole liver (G) and isolated primary hepatocytes (H) showed stronger expression in WT compared than in NEMO^Δhepa^ mice. (I) TNF mRNA and cellular location indicated by IHC. (J) Western blotting showed phosphorylation of JNK1 (p45) and JNK2 (p54) in NEMO^f/f^ mice after Jo2. JNK1 and GAPDH act as loading controls. Bars, 50 µm. Data are representative of three independent experiments. *n* = 4. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (NEMO^f/f^ vs. NEMO^Δhepa^). §§, P \< 0.01; §§§, P \< 0.001 (NEMO^f/f^ vs. Jo2/NEMO^f/f^). Error bars represent SD.](JEM_20082152_RGB_Fig1){#fig1}

These data may seem contradictory to reports showing that NF-κB inhibition sensitizes hepatocytes to Fas apoptosis ([@bib4]). However, as we previously described, NF-κB is one of the main factors responsible for activating *Fas* transcription ([@bib9]). Thus, we hypothesized that NEMO^Δhepa^ mice might have a defective turnover of this receptor, thereby promoting resistance to Jo2 apoptosis. In agreement with this, NEMO^Δhepa^ mice exhibited reduced levels of Fas (25% less) and impaired up-regulation of Fas after Jo2 ([Fig. 1 G](#fig1){ref-type="fig"}). IHC confirmed these results, as Fas staining was almost negative on NEMO^Δhepa^ mice after Jo2 ([Fig. 1 G](#fig1){ref-type="fig"}). Messenger RNA (mRNA) analysis on isolated primary hepatocytes corroborated the inability of NEMO^Δhepa^ mice to express Fas ([Fig. 1 H](#fig1){ref-type="fig"}), which led to impaired NF-κB activation on these cells (not depicted).

Additionally, in accordance with the observation that Jo2/Fas induces TNF expression through NF-κB activation ([@bib12]), we found a strong up-regulation of TNF in NEMO^f/f^ mice after Jo2 (43-fold), whereas it was barely regulated in NEMO^Δhepa^ mice ([Fig. 1 I](#fig1){ref-type="fig"}). IHC on liver sections confirmed macrophages as the main source of TNF after Fas activation, which likely explains the modest TNF regulation observed in NEMO^Δhepa^ mice ([Fig. 1 I](#fig1){ref-type="fig"}).

Finally, NEMO^f/f^ mice displayed strong c-Jun N-terminal kinase (JNK) phosphorylation, whereas it remained inactive in NEMO^Δhepa^ mice after Jo2 ([Fig. 1 J](#fig1){ref-type="fig"}), supporting the absence of cellular stress in our KO animals upon Fas activation. These results suggest that Fas is not an essential mediator of the pathogenesis observed in NEMO^Δhepa^ mice.

Thus, we next investigated the potential implication of TRAIL in the initiation and progression of chronic liver damage in our NEMO-deficient mice. As expected, low doses of TRAIL had no effect on NEMO^f/f^ mice, as ALT levels and liver architecture remained unaffected ([Fig. 2, A and B](#fig2){ref-type="fig"}). In clear contrast, TRAIL had a strong impact on NEMO^Δhepa^ mice, as a significant rise in serum ALT and massive liver damage, indicated by profuse PMN infiltration, necrosis, and apoptosis, were observed ([Fig. 2, A and B](#fig2){ref-type="fig"}). TUNEL assay and caspase 3 activity confirmed the severity of TRAIL-mediated apoptosis on NEMO^Δhepa^ mice ([Fig. 2, C and D](#fig2){ref-type="fig"}). Previous work indicated that TRAIL induced JNK activation, leading to cellular apoptosis ([@bib5]). Accordingly, we found that TRAIL promoted strong JNK activation in NEMO^Δhepa^ livers, whereas it remained inactive in NEMO^f/f^ mice ([Fig. 2 E](#fig2){ref-type="fig"}). Moreover, TRAIL administration promoted a significant induction of TNF in NEMO^Δhepa^ mice that was confirmed by IHC, uncovering the Kupffer cells as its main source ([Fig. 2 F](#fig2){ref-type="fig"}). These results suggest that hepatocyte-NEMO deletion promotes hypersensitivity to TRAIL-mediated apoptosis; hence, we next attempted to elucidate the potential mechanisms underlying this effect.

![**NEMO^Δhepa^ mice are sensitive to low doses of TRAIL-mediated liver injury.** 25 mg/kg of flagged TRAIL was administered i.v. (A) ALT serum levels were significantly elevated in NEMO^Δhepa^ mice after TRAIL. (B--D) H&E staining (B), TUNEL assay (C), and caspase 3 activity (D) showed TRAIL-mediated liver damage and apoptosis in NEMO^Δhepa^ mice. (E) Western blot analysis showed JNK phosphorylation. JNK1 and GAPDH were used as loading controls. (F) RT-PCR analysis of TNF mRNA and IHC showed higher expression in NEMO^Δhepa^ mice. (G) mRNA analysis and IHC evidenced strong DR5 expression in NEMO^Δhepa^ livers compared with NEMO^f/f^. Bars, 50 µm. All data are representative of three independent experiments. *n* = 4. \*\*, P \< 0.01; \*\*\*, P \< 0.001 (NEMO^f/f^ vs. NEMO^Δhepa^). §§, P \< 0.01; §§§, P \< 0.001 (NEMO^Δhepa^ vs. TRAIL/NEMO^Δhepa^). Error bars represent SD.](JEM_20082152_RGB_Fig2){#fig2}

Interestingly, DR5 was highly expressed in livers of untreated NEMO^Δhepa^ mice, where it was mainly present in hepatocytes ([Fig. 2 G](#fig2){ref-type="fig"}). This was confirmed in vitro, where NEMO^Δhepa^ hepatocytes showed an eightfold increase in DR5 expression and a complete inability to activate NF-κB in response to TRAIL in contrast to WT cells ([Fig. S2, A and B](http://www.jem.org/cgi/content/full/jem.20082152/DC1)). Accordingly with our in vivo data, WT cells remained unaffected, whereas TRAIL induced JNK activation on hepatocytes lacking NEMO, leading to strong apoptotic cell death which was significantly abrogated by JNK inhibition with SP600125 (Fig. S2, C and D). The protection elicited by JNK inhibition, despite the absence of NF-κB in NEMO-deficient hepatocytes, suggests an essential role of DR5-JNK signaling during TRAIL-induced cellular damage in NEMO^Δhepa^ mice.

NK cells are the main producers of TRAIL in the liver ([@bib22]; [@bib23]). Earlier studies demonstrated that genetically or dietary-induced fatty liver disease promotes activation of these cells ([@bib3]; [@bib10]). Thus, we hypothesized that similar alterations in the innate immune system might also arise in livers of NEMO^Δhepa^ mice.

NEMO^Δhepa^ livers had significantly reduced numbers of NK and NKT cells compared with NEMO^f/f^ littermates ([Fig. 3 A](#fig3){ref-type="fig"}). As NK cells\' activation is associated with their apoptosis, the lower NK1.1^+^ cell number found in NEMO^Δhepa^ livers could reflect their activation. Hence, NK1.1^+^ cells from NEMO^Δhepa^ mice exhibited significantly higher levels of annexin V when compared with NEMO^f/f^ mice ([Fig. 3 B](#fig3){ref-type="fig"}). Activation of NK cells involves strong production of proinflammatory cytokines, like IFN-γ and IL-12, promoting their cytotoxic activity and apoptosis ([@bib28]). Accordingly, we found higher IFN-γ and IL-12 (p35) expression associated with lower IL-4 levels in NEMO^Δhepa^ mice compared with WT littermates. Additionally, higher CCL5 (RANTES) levels found in NEMO^Δhepa^ livers ([Fig. 3 C](#fig3){ref-type="fig"}) may reflect a compensatory response to restore liver NK cells number ([@bib17]). These data were confirmed on isolated NK1.1^+^ cells from livers of NEMO^Δhepa^ mice showing higher IFN-γ and CCL5 but lower IL4 levels ([Fig. 3 D](#fig3){ref-type="fig"}). FACS and mRNA analysis evidenced strong TRAIL expression on liver NK1.1^+^ cells from NEMO^Δhepa^ compared with WT mice ([Fig. 3 E](#fig3){ref-type="fig"}).

![**Hepatocyte-specific deletion of NEMO promotes spontaneous activation of liver NK/NKT cells, and administration of NK1.1-depleting mAb attenuates the damaging phenotype in NEMO^Δhepa^ mice.** (A) FACS analysis revealed a lower number of NK1.1^+^CD3^−^ and NK1.1^+^CD3^+^ cells in NEMO^Δhepa^ mice. The graph represents the percentage of NK1.1^+^ cells related to the percentage of CD45^+^ cells in the liver (B) FACS analysis of NK1.1^+^/annexin V^+^ related to % of CD45^+^ cells revealed strong apoptosis of NK1.1^+^ cells in livers from NEMO^Δhepa^ mice. (C) RT-PCR showed strong expression of IL-12 (p35), IFN-γ, and CCL5 but lower IL-4 mRNA in livers. Data are presented as times versus NEMO^f/f^ untreated. (D) mRNA analysis of isolated NK1.1^+^ cells confirmed cell activation and increased cytokine expression. (E) FACS analysis showed stronger TRAIL expression on NK1.1^+^ cells from livers from NEMO^Δhepa^ mice. mRNA analysis on isolated NK1.1^+^ cells confirmed this. (F and G) FACS analysis proved effective depletion of NK1.1^+^ cells (F) 40 h after NK1.1 mAb administration that reduced IFN-γ and CCL5 mRNA levels (G). (H--J) Serum ALT (H), H&E staining (I), and FACS analysis (J; CD11b^+^ cells) were used as markers of liver damage and inflammation. Bars, 50 µm. All data are representative of three independent experiments. *n* = 4. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (NEMO^f/f^ vs. NEMO^Δhepa^). §§, P \< 0.01 (NEMO^Δhepa^ vs. Nk1.1mAb/NEMO^Δhepa^). Error bars represent SD.](JEM_20082152_RGB_Fig3){#fig3}

These data suggest that hepatocyte-NEMO deletion correlates with an altered NK/NKT cell response. Moreover, the proclivity of TRAIL-producing NK cells to promote cytotoxicity against self-hepatocytes ([@bib18]) appears to be enhanced in NEMO^Δhepa^ mice, suggesting that this may represent a potential mechanism involved in the chronic inflammation and parenchymal damage observed in NEMO^Δhepa^ mice.

To test this hypothesis, we investigated the potential beneficial effects of NK/NKT cell inactivation in NEMO^Δhepa^ mice by using a NK1.1 mAb (PK-136). FACS and mRNA analysis confirmed efficient cell depletion after NK1.1 mAb administration ([Fig. 3 F](#fig3){ref-type="fig"}) that attenuated IFN-γ and CCL5 expression, correlating with strong amelioration of liver damage in NEMO^Δhepa^ mice ([Fig. 3, H and I](#fig3){ref-type="fig"}). FACS analysis confirmed the attenuation of the proinflammatory environment in NK1.1 mAb-treated NEMO^Δhepa^ mice, as a significant reduction of CD11b^+^ cells was detected ([Fig. 3 J](#fig3){ref-type="fig"}).

Based on our present data, which identify the critical detrimental role of NK1.1^+^ cells in the pathogenesis of liver injury in NEMO^Δhepa^ mice ([Fig. 3](#fig3){ref-type="fig"}), we further characterized the contribution of these cells during concanavalin A (ConA) hepatitis, where NKT cells activation have a major implication ([@bib25]; [@bib24]).

Administration of 15 mg/kg ConA caused 100% mortality of NEMO^Δhepa^ mice within 16 h, whereas all NEMO^f/f^ mice survived ([Fig. S3](http://www.jem.org/cgi/content/full/jem.20082152/DC1)). To better define the molecular mechanism leading to the mortality of NEMO^Δhepa^ mice, we next administered 25 mg/kg ConA and sacrificed the animals 6 h after injection. ConA triggered a more severe hepatitis in NEMO^Δhepa^ mice compared to NEMO^f/f^ littermates. Massive destruction of liver parenchyma in NEMO^Δhepa^ mice were indicated by high ALT, strong inflammation, and necrotic and apoptotic cell death ([Fig. 4, A--C](#fig4){ref-type="fig"}). Moreover, ConA induced significantly higher levels of IFN-γ, IL-4, and CCL5 in NEMO^Δhepa^ compared with NEMO^f/f^ livers ([Fig. 4 D](#fig4){ref-type="fig"}). ELISA confirmed systemic IFN-γ elevation ([Fig. 4 E](#fig4){ref-type="fig"}).

![**ConA promotes stronger liver damage in NEMO^Δhepa^ mice than in NEMO^f/f^ animals.** (A--C) ALT serum levels (A), H&E staining and TUNEL analysis (B), and quantification of caspase 8 and 3 activity (C) measured 6 h after 25 mg/kg ConA showed strong liver damage in NEMO^Δhepa^ mice. (D) mRNA levels of IFN-γ, IL-4, CCL5, IL-12p35, TNF, and IL-10. All RT-PCR data are presented as times versus NEMO^f/f^ untreated. (E) ELISA of IFN-γ and TNF in serum before and 6 h after 25 mg/kg ConA. Bars, 50 µm. All data are representative of three independent experiments. *n* = 4. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (NEMO^f/f^ vs. NEMO^Δhepa^). §§, P \< 0.01; §§§, P \< 0.001 (NEMO^Δhepa^ vs. ConA/NEMO^Δhepa^). Error bars represent SD.](JEM_20082152_RGB_Fig4){#fig4}

Activated macrophages are the main producers of IL-12, which promotes NKT cell activation and further IFN-γ production ([@bib27]). This phenomenon may also occur in NEMO^Δhepa^ mice, as IL12-p35 was significantly upregulated before ConA and was further increased following injury ([Fig. 4 D](#fig4){ref-type="fig"}).

Expression of the antiinflammatory cytokine IL-10, which negatively regulates TNF, IFN-γ, and IL-12 after ConA ([@bib11]), was significantly lower in NEMO^Δhepa^, indicating their inability to orchestrate a proper antiinflammatory response to ConA hepatitis ([Fig. 4 D](#fig4){ref-type="fig"}). As expected, up-regulation of TNF was observed in WT and NEMO^Δhepa^ mice after ConA but no significant differences were observed between genotypes ([Fig. 4, D and E](#fig4){ref-type="fig"}).

NK/NKT cell depletion lead to a remarkable improvement of liver parenchyma, indicated by lower ALT, necrosis, inflammation, and infiltration of PMNs ([Fig. 5, A and B](#fig5){ref-type="fig"}). Attenuation of ConA induced liver apoptosis after NK1.1 mAb treatment was confirmed by TUNEL assay and caspase 8 activity ([Fig. 5 C](#fig5){ref-type="fig"}). Accordingly, IFN-γ, CCL5, and IL-4 levels were lower after ConA in NK1.1-depleted NEMO^Δhepa^ mice ([Fig. 5 D](#fig5){ref-type="fig"}), and systemic IFN-γ and TNF serum levels were significantly reduced ([Fig. 5 E](#fig5){ref-type="fig"}). Remnant cytokine expression despite NK1.1 mAb is likely explained by the fact that ConA promotes activation of other cell compartments like macrophages.

![**NK1.1 cell depletion and adoptive transfer of TRAIL^−/−^ MNCs protects NEMO^Δhepa^ mice against ConA-mediated fulminant hepatitis.** (A--C) ALT serum levels (A), H&E staining (B), TUNEL analysis, and quantification of caspase 8 (C), 6 h after 25 mg/kg ConA revealed strong attenuation of ConA hepatitis in NEMO^Δhepa^ mice when NK1.1 mAb was administered 40 h before insult. (D and E) mRNA levels of IFN-γ, CCL5, and IL-4 (D) and ELISA of IFN-γ and TNF (E) on serum confirmed attenuation of ConA damage in NEMO^Δhepa^ mice after NK1.1 mAb. (F--H) Adoptive transfer of TRAIL^−/−^ MNCs and liver TRAIL^−/−^ NK1.1^+^ cells after NK1.1 mAb protected while TRAIL^+/+^ MNC transfer restored ConA injury in NEMO^Δhepa^ mice as shown by serum ALT (F), H&E staining (G), and ELISA (H) of IFN-γ serum levels. (I) ConA-mediated JNK activation was attenuated by NK1.1 mAb and restored by TRAIL^+/+^ MNCs adoptive transfer. TRAIL^−/−^ cells maintained JNK inactivated. JNK1 and GAPDH act as loading control. Bars, 50 µm. All data are representative of three independent experiments. *n* = 4. \*\*, P \< 0.01; \*\*\*, P \< 0.001 (NEMO^Δhepa^ vs. ConA/NEMO^Δhepa^). §, P \< 0.05; §§, P \< 0.01; §§§, P \< 0.001 (ConA/NEMO^Δhepa^ vs. NK1.1mAb/ConA/NEMO^Δhepa^).](JEM_20082152_RGB_Fig5){#fig5}

Recent work showing that TRAIL^−/−^ mice are protected from ConA-induced liver injury highlighted the important role of TRAIL in this model ([@bib29]). Thus, we examined if this cytokine may be an essential mediator of ConA liver damage in our NEMO^Δhepa^ mice. We performed intrahepatic adoptive transfer of splenic mononuclear cells (MNCs) from TRAIL^−/−^ or TRAIL^+/+^ mice before ConA administration in NK1.1^+^-depleted mice. Liver damage was strongly attenuated in NEMO^Δhepa^ mice receiving TRAIL^−/−^ MNCs in contrast to TRAIL^+/+^ MNC transferred mice, where injury was restored ([Fig. 5, F and G](#fig5){ref-type="fig"}). Additionally, adoptive transfer of TRAIL^+/+^ MNCs into NK1.1-depleted NEMO^Δhepa^ mice restored both liver and systemic IFN-γ expression after ConA, whereas it remained low in NEMO^Δhepa^ mice receiving TRAIL^−/−^ MNCs ([Fig. 5 H](#fig5){ref-type="fig"}). The essential implication of NK cell--derived TRAIL in mediating ConA hepatitis in NEMO^Δhepa^ mice was further confirmed by adoptive transfer of isolated NK1.1^+^ cells from TRAIL^−/−^ mice, which preserved liver protection against ConA injury elicited by NK1.1 mAb ([Fig. 5, F--H](#fig5){ref-type="fig"}).

During ConA-mediated hepatitis, JNK activation is related to the degree of apoptosis and the severity of the cellular stress ([@bib26]). Additionally, we showed the detrimental effects of the TRAIL-JNK cascade in NEMO^Δhepa^ mice both in vivo and in vitro ([Fig. 2](#fig2){ref-type="fig"} and Fig. S2). Accordingly, strong JNK activation was observed in NEMO^Δhepa^ mice after ConA, whereas it was clearly blunted after NK1.1 mAb despite ConA administration ([Fig. 5 I](#fig5){ref-type="fig"}). JNK activation was restored after adoptive transfer of TRAIL^+/+^ MNCs in NEMO^Δhepa^ livers after ConA despite NK1.1 mAb treatment. On the contrary, transfer of both TRAIL^−/−^ MNCs and TRAIL^−/−^ NK1.1^+^ cells maintained the resistance of NK1.1-depleted NEMO^Δhepa^ mice to ConA-mediated JNK activation ([Fig. 5 I](#fig5){ref-type="fig"}).

Previous studies using a NK1.1 mAb described that NKT cells are an essential cell subset responsible for ConA-mediated liver injury as selective depletion of NK cells with an anti-asialo GM1 antibody had no impact on ConA hepatitis ([@bib25]). However, our present data strongly support the hypothesis that NK cell--derived TRAIL plays a key role in the progression of ConA-induced liver damage in NEMO^Δhepa^ mice. Accordingly, we observed that NK cell depletion with asialo-GM1 mAb significantly reduced ALT levels (2.17-fold; [Fig. S4 A](http://www.jem.org/cgi/content/full/jem.20082152/DC1)), a comparable effect to that observed with NK1.1 mAb ([Fig. 5 A](#fig5){ref-type="fig"}; 2.56-fold reduction). Accordingly, hematoxylin and eosin (H&E) and TUNEL assay revealed significant protection against ConA after NK cell depletion (Fig. S4, B and C), accompanied by reduced CCL5 in asialo-GM1--treated NEMO^Δhepa^ mice. Interestingly, despite the clear protection elicited by NK cell depletion, we found high IL-4 mRNA expression in asialo-GM1 mAb--treated KOs (Fig. S4 D) suggesting remnant activation of NKT cells. Moreover, downregulation of serum IFN-γ levels supports the implication of this cytokine in the activation and production of TRAIL from NK cells in an autocrine fashion ([@bib22]; [@bib23]). This data strongly supports the essential role of TRAIL-producing NK cells in mediating the dramatic impact of ConA on NEMO^Δhepa^ mice.

Our present study uncovers a new mechanism by which hepatocyte-specific NEMO deletion contributes to spontaneous liver inflammation and injury. We show that NEMO deletion sensitizes the liver to TRAIL-mediated apoptosis and this contributes to disease progression. We propose a dual mechanism consisting of up-regulation of DR5 on hepatocytes and the activation of TRAIL-producing NK cells to cause the detrimental effects of NEMO deletion in the liver. The first mechanism is supported by studies showing that steatosis and free fatty acids promote up-regulation of DR5 mRNA expression ([@bib16]). Additionally, the profuse bile acid accumulation found in livers of NEMO^Δhepa^ mice (unpublished data) may further promote DR5 expression ([@bib7]). In addition to increased DR5 expression, fatty liver disease also triggers NKT cell activation, leading to a proinflammatory cytokine response ([@bib10]), which we also observed in our NEMO^Δhepa^ mice.

Additionally, it has been shown that NKT cells promote NK cell activation and TRAIL production through IFN-γ expression ([@bib22]). At present, the relevance of intestinal bacterial products transported into the liver through the blood stream and its role in NK and NKT cell activation is unclear in this model. However, this mechanism could also be relevant, as LPS induces macrophages to produce IL-12, triggering IFN-γ production by NKT cells in the absence of IL-4 ([@bib1]; [@bib3]). This scenario closely resembles the liver environment found in untreated NEMO^Δhepa^ mice.

Our present work strengthens the essential role of hepatocyte NEMO/NF-κB to maintain liver homeostasis because absence of NEMO in these cells activates the innate immune system, thus promoting liver damage. The cascade of molecular events leading from steatohepatitis to fibrosis and tumor development observed in NEMO^Δhepa^ mice reflects the pathogenesis of liver cirrhosis and HCC in humans. Further work in this model could yield novel therapeutic strategies targeting the NK cell/TRAIL axis to modulate chronic liver disease progression.

MATERIALS AND METHODS
=====================

### Generation of hepatocyte-specific conditional NEMO KO mice.

We generated mice carrying the loxP site--flanked (floxed \[f\]) *NEMO* gene (NEMO^f/f^) as described in detail in the supplemental figures. We generated NEMO^Δhepa^ mice by crossing NEMO^f/f^ with alfp-cre transgenic animals. For the experiments described, we used 8-wk-old male (Jo2 and TRAIL \[provided by S. Bronk, Mayo Clinic College of Medicine, Rochester, MN) and female (NK1.1 mAb and ConA) mice. Animals were treated according to the guidelines of the National Academy of Sciences (National Institutes of Health publication 86-23, revised 1985). Animal husbandry and procedures were approved by the authority for environment conservation and consumer protection of the state North Rhine--Westfalia (LANUV) and the University Hospital Aachen Animal Care Facility\'s guidelines.

### Models of liver injury.

Jo2 (0.5 µg/g of body weight; BD) was injected i.p. and mice were sacrificed 3 h later. ConA (Sigma-Aldrich) was administered i.v. for either 6 h (15 mg/kg of body weight) or 24 h (25 mg/kg). Flagged TRAIL ([@bib6]) was administered i.v. at a concentration of 25 mg/kg.

### Analysis of gene and serum protein expression.

RNA was isolated with PeqGold-RNA pure kit (PEQLAB) from livers. Quantitative real-time PCR was performed using SYBR green reagent (Invitrogen) in a 7300 Real-Time PCR system (Applied Biosystems). GAPDH was used to normalize gene expression, which is represented as times versus NEMO^f/f^ basal expression. Liver and serum TNF and serum IFN-γ levels were quantified by ELISA (R&D systems and BD, respectively).

### Western blotting.

Immunoblotting on liver protein extracts were performed with IKKγ/NEMO, p65, and JNK1 (Santa Cruz Biotechnology Inc.), phospho-JNK1/JNK2 (Tyr183/185; Invitrogen), and GAPDH antibody (Biogenesis).

### Histological evaluation and apoptosis determination.

H&E staining was performed on paraffin-embedded liver sections. Apoptosis was evaluated by TUNEL assay performed on frozen liver sections using the in situ cell death detection kit (Roche) according to manufacturer\'s instructions. Caspase 8 and 3 activity were quantified on liver protein extracts as previously described ([@bib13]). DR5 detection on liver sections was performed by IHC using a DR5 antibody (ProScience), followed by Cy-3--labeled secondary antibody (Jackson ImmunoResearch Laboratories) or by the polyclonal Enhanced Vision reaction (Dako). TNF IHC was performed on frozen sections using rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.).

### NK1.1^+^ cell depletion.

NK1.1 antibody (250 µg/mouse i.p.) was purified from hybridoma PK-136 (American Type Culture Collection) culture supernatants. Depletion efficiency was determined by FACS analysis 40 h after administration. NK cell--specific depletion was obtained by i.p. administration of 250 µg Asialo-GM1 mAb (Wako Chemicals USA, Inc.) per mouse.

### MNC isolation, adoptive transfer, and flow cytometric analysis.

Liver and splenic MNCs were obtained as previously described ([@bib29]) with small modifications. In brief, MNCs were isolated by collagenase digestion and erythrocytes were removed using PharmLyse lysing buffer (BD). MNCs were purified by density gradient centrifugation using Lymphocyte (LSM 1077; PAA). 2 × 10^7^ splenic MNCs were injected in the lateral left liver lobe of NEMO^Δhepa^ mice using a 29-gauge needle 1 h before i.v. administration of 25 mg/kg ConA.

### Flow cytometry analysis and cell sorting.

Cells were stained with CD45-APC-Cy7, NK1.1-PE-Cy7, CD11b-PE, annexin V--FITC (BD), and CD3-APC (eBioscience). All samples were analyzed by flow cytometry (FACS Canto II; BD). For NK cell isolation, livers cells were isolated, stained, and purified by high speed sorting using a FACSAria (BD). CD45^+^NK1.1^+^ cells were further analyzed or transferred into animals while CD45^+^CD19^+^ cells were discarded. Purity of isolated NK1.1^+^ cells was \>98%.

### Statistical analysis.

Data are expressed as mean ± standard deviation of the mean. Statistical significance was determined by two-way analysis of variance followed by a Student\'s *t* test.

### Online supplemental material.

Fig. S1 shows the gene-targeting strategy for the generation of hepatocyte-specific NEMO KO mice. Fig. S2 demonstrates the effect of TRAIL on primary hepatocytes. Fig. S3 shows the survival curve after ConA treatment. Fig. S4 shows the effects of asialo-GM1 mAb administration during ConA hepatitis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20082152/DC1>.
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